Skip to main content

Market Overview

Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting

Share:
Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting

Analysts at Cantor Fitzgerald continue to hold a bullish stance on Spark Therapeutics Inc (NASDAQ: ONCE) after the U.S. Food and Drug Administration gave the company a critical recommendation for its therapy called Luxturna. Analyst Elemer Piros maintains an Overweight rating on Spark's stock with a price target raised from $94 to $105.

Luxturna, Spark's therapy for the treatment of biallelic RPE65 mutation-associated retinal dystrophy, voted by an FDA advisory committee panel 16-0 to recommend the drug's approval on Thursday, the analyst said. Luxturna is now one step closer to becoming the first ever approved gene therapy for the treatment of any genetic condition in the U.S.

Spark's therapy was able to show "unprecedented and impressive" reversal of the disease, Piros said. While one of the panelists did recommend a re-calibration of the multi-luminance mobility test's (MLMT) primary endpoint to become more meaningful, the overall conclusion was that "no better tools exist and that results were clinically meaningful."

Physicians and surgeons who took part in the FDA's discussion "reflected reassurance and comfort on the overall safety profile." Also, while Luxturna is intended for patients three years and older some members of the panel contemplated the possibility of dosing younger patients.

The analyst's probability of ultimate FDA approval for a launch has been boosted from 95 percent to 100 percent and a quick approval is now expected prior to Luxturna's PDUFA date, which is scheduled for Jan. 12, 2018.

Related Links:

A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Wells Fargo Earnings

7 Stocks To Watch For October 13, 2017

Latest Ratings for ONCE

DateFirmActionFromTo
Mar 2019BarclaysDowngradesOverweightEqual-Weight
Feb 2019Stifel NicolausDowngradesBuyHold
Feb 2019BernsteinDowngradesOutperformMarket Perform

View More Analyst Ratings for ONCE
View the Latest Analyst Ratings

 

Related Articles (ONCE)

View Comments and Join the Discussion!

Posted-In: Blind Cantor FitzgeraldAnalyst Color News Price Target FDA Top Stories Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com